Sobi has today communicated its offer to acquire CTI BioPharma (CTI), a US listed company within hematology, for USD 9.10 per share, equivalent to an enterprise value of USD 1.7bn and to carry out a rights issue with preferential rights for existing shareholders to partially finance the acquisition. Investor AB, Sobi’s largest owner, with an ownership of 34.7 per cent of the capital and votes, supports the bid and has undertaken to subscribe for its pro rata share in the rights issue corresponding to SEK 2.9bn.
“Investor was instrumental in the creation of Sobi close to 15 years ago. Sobi has during our ownership successfully built a leading hemophilia franchise, broadened its product portfolio and expanded geographically. We support the acquisition of CTI, which is in line with the company’s strategy to continue broadening its product portfolio within prioritized areas as well as strengthening its US presence”, says Investor’s President and CEO Johan Forssell.
Investor, founded by the Wallenberg family in 1916, is an engaged owner of high quality global companies. We have a long-term investment perspective. Through board participation, as well as industrial experience, our network and financial strength, we work continuously to support our companies to remain or become best-in-class. Our holdings include, among others, ABB, Atlas Copco, Ericsson, Mölnlycke and SEB.